Hearn Cho, MD
Medical Oncology · New York, NYNPI 1225060080
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Bristol Myers Squibb at 46.0% of the total. Reporting peaked in 2019 at $22,619 and has fallen 98.0% since, to $461 in 2025.
Across 40 payments — averaging $1072.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$20K
- E.r. Squibb & Sons, L.L.C.$8K
- F. Hoffmann-la Roche AG$6K
- Amgen$3K
- GSK$2K
- Epizyme, Inc.$2K
- plus $2K from 11 others
Across 57 payments — averaging $168,518 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$3.2M
- Pfizer$3M
- Genentech, Inc.$1.7M
- Takeda Pharmaceuticals U.S.A., Inc.$1.2M
- GSK$571K
- E.r. Squibb & Sons, L.L.C.$25K
What the payments were for
- Consulting fees$21,99251%
- Speaking & faculty fees$1,9855%
- Travel & lodging$16,02637%
- Food & beverage$1,7354%
- Gifts$1,1603%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 3 | $19,745 |
| E.r. Squibb & Sons, L.L.C. | 6 | $7,996 |
| F. Hoffmann-la Roche AG | 8 | $6,078 |
| Amgen | 2 | $3,254 |
| GSK | 5 | $2,059 |
| Epizyme, Inc. | 1 | $1,500 |
| Sekisui Diagnostics LLC | 4 | $1,160 |
| American Orthodontics Corporation | 1 | $276 |
| Foundation Medicine, Inc. | 1 | $229 |
| Johnson & Johnson | 2 | $190 |
| Genentech, Inc. | 1 | $149 |
| Janssen Research & Development, LLC | 1 | $130 |
| Pfizer | 1 | $47 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| AbbVie | 1 | $23 |
| Sanofi | 1 | $21 |
| Regeneron | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Revlimid$19,722
- TAZVERIK$1,500
- TECENTRIQ$485
- EMPOWER-METAL$276
- EMPOWER-CERAMIC$276
- RADIANCE$276
- MASTER SERIES$276
- LP AND IFIT TUBES$276
- FOUNDATIONONE CDX$229
- CARVYKTI$114
- DARZALEX$114
- TECVAYLI$114
- TALVEY$114
How this compares
$42,898 in reported general payments places this provider in the 75th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 61 | $546 |
| Gabapentin | 17 | $129 |
| Dexamethasone | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.